|
 |
C O N T E N T S
EDITORIAL
TREATMENT ALERT
CONFERENCE REPORT
13th International Conference on AIDS and STIs in Africa (ICASA), 21-26 September 2003, Nairobi, Kenya
CONFERENCE REPORT
Reports from 43rd ICAAC, 14-17 September 2003, Chicago
- ddI may retain activity in nucleoside experienced patients
- Studies and strategies with existing drugs
- Incremental progress with new antiviral drugs
- Newer nucleoside analogues show fewer adverse effects
PHARMACOLOGY STUDIES
- Interaction between amprenavir and lopinavir thwarts triple PI salvage
- Vitamin C induces P4503A4 and reduces indinavir levels
- Indinavir levels reduced by omeprazole
- Boosted saquinavir PK in once-daily regimes
- Tenofovir drug-drug interactions
- Summary of other PK studies
TREATMENT ACCESS
- Global AIDS spending must double by 2005, says gloomy UN
- GARPP requests permission from Boehringer to import generic nevirapine
- Canada decides to lead the way in exempting AIDS drugs from patent laws
ANTIRETROVIRALS
- Atazanavir ‘named-patient’ access extended in the UK and includes 150mg capsule
- Another triple nuke failure: abacavir/ddI/d4T
- FDA announces changes to ritonavir package insert
TREATMENT INTERRUPTIONS
- Treatment interruption prior to five-drug regime shows no benefit at 48 weeks
- Failure of alternating week-on and week-off therapy
METABOLIC COMPLICATIONS
OPPORTUNISTIC INFECTIONS
WOMEN AND HIV
- Antiviral dynamics and sex differences of AZT and 3TC triphosphate concentrations
- Women have a greater immunological response to effective HAART
MATERNAL HEALTH & MOTHER TO CHILD TRANSMISSION
PAEDIATRICS
- Rituximab as single agent reversed paediatric Non-Hodgkins Lymphoma (NHL)
- Perinatal antiretroviral treatment and haematopoiesis in HIV-uninfected infants
COINFECTION
OTHER NEWS
ON THE WEB
PUBLICATIONS AND SERVICES FROM i-BASE
h-tb HIV Treatment Bulletin HTB is a monthly journal published in print and electronic format by HIV i-Base. As with all i-Base publications, subscriptions are free and can be ordered directly from the i-Base website: http://www.i-Base.info by sending an email to: HTB is a not-for-profit community publication that aims to provide a review of the most important medical advances related to clinical management of HIV and its related conditions as well as access to treatments. Some articles are reproduced from other respected sources and copyright for these articles remains with the original authors and sources, as indicated at the end of each article. We thank those organisations for recognising the importance of providing widely distributed free access to information both to people living with HIV and to the healthcare professionals involved in their care. We also thank them for permission to distribute their excellent work and we encourage HTB readers to visit the source websites for further access to their coverage of HIV treatment. Articles written and credited to i-Base writers, as with all i-Base originated material, remains the copyright of HIV i-Base, but these articles may be reproduced by community and not-for-profit organisations without individual written permission and reproduction is encouraged. A credit and link to the original author, the HTB issue and the i-Base website is always appreciated. |
Editor in Chief: Paul Blanchard Editor: Simon Collins Associate Editor: Graham McKerrow Commissioning Editor: Polly Clayden Medical Consultants:
HIV
i-Base HIV i-Base is a registered charity no 1081905 and company reg no 3962064. HTB is also known as DrFax |